Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24924613 | 1.00 | DPP4 (0.38) | DPP4DPP9ALDH1A1TSHRNOS2 | |
| SCHEMBL18281192 | 0.79 | DPP7 (0.40) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL11342489 | 0.79 | SLC1A2 (0.42) | DPP4DPP9ALDH1A1TSHR | |
| SCHEMBL8207593 | 0.79 | SLC1A2 (0.42) | DPP4DPP9ALDH1A1TSHR | |
| SCHEMBL13745182 | 0.79 | DPP4 (0.39) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL13745633 | 0.79 | DPP4 (0.39) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL18281190 | 0.79 | DPP7 (0.40) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL3092715 | 0.77 | DPP4 (0.38) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL5789355 | 0.76 | ALOX15 (0.56) | DPP4DPP9NOS2NOS3NOS1 | |
| SCHEMBL16240926 | 0.76 | DPP4 (0.62) | DPP4DPP9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257405-A1 | METHOD FOR PREPARING GLUFOSINATE OR ANALOGUES THEREOF | LIER CHEMICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257405-A1 | METHOD FOR PREPARING GLUFOSINATE OR ANALOGUES THEREOF | LIER CHEMICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4219512-A1 | METHOD FOR PREPARING GLUFOSINATE OR ANALOG THEREOF | Lier Chemical Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023001132-A1 | METHOD FOR PREPARING GLUFOSINATE OR ANALOG THEREOF | 利尔化学股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257405-A1 | METHOD FOR PREPARING GLUFOSINATE OR ANALOGUES THEREOF | FPGS, TYMP, GLUL | DPP4 469/4885DPP9 651/4885ALDH1A1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.